EMB-01 is an EGFR- and cMET-targeted bispecific antibody based on the FIT-Ig technology platform, which fuses the Fab of an anti-cMET antibody to the variable region of an anti-EGFR antibody to form a ...

About Bambusa's pipeline BBT001 is a novel half-life extended bispecific antibody. Preclinical data with BBT001 demonstrate its best-in-disease potential, offering enhanced efficacy and improved ...

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical ...

Zymeworks Inc. announced that their bispecific antibody, zanidatamab, has received conditional approval from China's National Medical Products Administration (NMPA) for treating previously treated ...

This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to ...

Bispecific antibody drug conjugates (BsADCs) are an innovative class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies with the cytotoxic payloads characteristic of ...

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical ...

Bispecific antibody drug conjugates (BsADCs) are an innovative class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies with the cytotoxic payloads ...

SCOTCH PLAINS, N.J., May 29, 2025--(BUSINESS WIRE)--Navigator Medicines, Inc., a clinical-stage biotech company leading the advancement of biologics for targeted immune regulation and restoration ...